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Despite common pathological features, gastroenteropancreatic
(GEP) neuroendocrine tumours (NET) are a heterogeneous group
of tumours arising from diverse sites, presenting with different
clinical syndromes or biological activity, different aggressiveness
and prognosis. Up to now, treatment of GEP NET has been chal-
lenging, especially when the tumours are metastatic, since data
concerning the prognosis factors are still scarce. Age, tumour size,
stage and primary site may be related to the outcome of NET
(Johnson et al, 1983; McDermott et al, 1994; Greenberg et al,
1987; Modlin and Sandor, 1997). According to Warren and
Gould’s classification (Gould et al, 1983; Warren et al, 1989),
well-differentiated, moderately differentiated and poorly differen-
tiated NET should also be distinguished since this classification
has a therapeutic and prognostic impact. Finally, biological
activity of GEP NET may also have an impact on survival (Janson
et al, 1997; Baudin et al, 1999). Chromogranin A (CgA) has been
recently shown to be an independent prognosis factor of midgut
NET (Janson et al, 1997). However, we have demonstrated that
CgA level was independently correlated with tumour burden but
also with biological activity of NET (Baudin et al, 1998).
Treatment options should take into account these parameters.
Surgery is the only curative modality of GEP NET, but in cases
of unresectable tumour many options are available. In well-
differentiated NET, careful observation may be the best attitude
for patients with indolent, non-functional and slow-growing
metastatic tumour. In case of progressive well-differentiated
NET chemotherapy and/or biotherapies (interferon, somatostatin
analogues) and/or local treatments (arterial ligation, chemo-
embolization) may provide an effective palliation of symptoms
and allow improvements in the quality of life in symptomatic
tumours and in survival in pancreatic GEP NET (Oberg, 1994).
In contrast to well-differentiated NET, the aggressiveness of
poorly differentiated NET is similar to small-cell lung cancer
(SCLC), resulting in a median survival of 6 months without treat-
ment (Johnson et al, 1983; Staren et al, 1988; Rindi et al, 1996).
Most patients have metastatic disease and poor condition at the
time of diagnosis and cannot be approached surgically with cura-
tive intent (Hainsworth et al, 1988; Pelley and Bukowski, 1997).
In 1991, Moertel et al reported their experience with a regimen
combining etoposide (VP16) and cisplatin (CDDP) (Moertel et al,
1991). A major therapeutic activity was found in 18 patients with
poorly differentiated NET with an objective response (OR) rate of
67% and a median duration of response of 8 months. In contrast,
the OR rate in 27 patients with well-differentiated NET was only
7%. Since this publication, the association of VP16 and CDDP has
been considered as the reference treatment for poorly differenti-
ated NET. However, confirmatory studies are still lacking. Due to
the rarity of the NET, retrospective analyses are justified to further
assess its anti-tumoural efficacy and to define prognostic factors.
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Summary The purpose of this study was to evaluate by a retrospective analysis of 53 patients the efficacy of chemotherapy combining
etoposide and cisplatin in the treatment of neuroendocrine tumours. The regimen was a combination of etoposide 100 mg m–2 day–1 for 3 days
and cisplatin 100 mg m–2 on day 1, given by 2-h intravenous infusion, administered every 21 days. Twelve patients had a well-differentiated
and 41 a poorly differentiated neuroendocrine tumour. Toxicity of treatment was assessed in 50 patients and efficacy in 52 patients. Among
the 11 patients with a well-differentiated tumour evaluable for tumoural response, only one (9.4%) had a partial response for 8.5 months.
Forty-one patients with a poorly differentiated tumour showed an objective response rate of 41.5% (four complete and 13 partial responses);
the median duration of response was 9.2 months, the median overall survival 15 months and the median progression-free survival
8.9 months. Haematological grade 3–4 toxicity was observed in 60% of the cases with one treatment-related death, digestive grade 3–4
toxicity in 40% and grade 3 alopecia was constant. No severe renal, hearing and neurological toxicities were observed (grade 1 in 6%, 14%,
72% respectively and no grade >1). We confirm that poorly differentiated neuroendocrine tumours are chemosensitive to the etoposide plus
cisplatin combination. However, the prognosis remains poor with a 2-year survival lower than 20% confirming that new therapeutic strategies
have to be developed. © 1999 Cancer Research Campaign
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Patients
Fifty-three patients (36 males, 17 females) were treated at the
Gustave-Roussy Institute with a VP16–CDDP combination
between November 1988 and April 1997.
Criteria of eligibility were histologically confirmed, measurable
and inoperable NET. Systematic pathological review of histologic
material was performed before chemotherapy by a panel of pathol-
ogists (coordinated by JCS) and patients were classified as having
a well-differentiated or poorly differentiated NET according to the
Warren and Gould classification (Gould et al, 1983; Warren et al,
1989). All tumours disclosed NET morphological features
including regular cells, normochromatic nucleus and eosinophilic
cytoplasm arranged in ribbons, nests or sheets separated by a fine
fibrovascular stroma. An immunohistochemical study with
neuron-specific enolase (NSE), CgA and synaptophysin anti-
bodies (Dako, Gioostsup, Denmark) was performed when the
morphological structure precluded an unequivocal diagnosis of
NET. GEP NET were classified according to their primary site as
foregut (head and neck, respiratory tract, pancreas, stomach,
duodenum), midgut (ileum, appendix, right colon) and hindgut
(left colon, rectum, uterus) (Williams and Sandler, 1963). Patients
with mixed tumours and small-cell lung carcinomas were
excluded. Patients with neutropenia < 1500 mm–3 thrombocyto-
penia < 100 000 mm–3, serum creatinine >125 mg–1 or uncon-
trolled infection were excluded from the study.
The staging procedures performed before starting treatment
included a physical examination, biochemical profile, chest X-ray,
abdominal ultrasound and thoraco-abdominal computerized
tomography (CT) scan. Since 1993, In-111-DTPA-octreotide
scintigraphy (octreoscan) has been systematically performed in
well-differentiated NET, but only in a few patients with poorly
differentiated NET considering its low sensitivity in these patients
in our experience (data not shown). Additional procedures (diges-
tive endoscopy, bronchoscopy, brain and/or bone CT scan, bone
scintigraphy) were carried out according to clinical presentation
and tumour location. Since 1993, hormonal tumour marker
screening was standardized as described previously (Baudin et al,
1999). Briefly, NSE or CgA, 5-hydroxyindolacetic acid (5-HIAA),
calcitonin (CT) and glycoprotein a-subunit (aGP) were measured
in foregut-derived NET, only NSE or CgA and 5-HIAA measure-
ments in midgut-derived NET. Hormonal hypersecretion was
defined as values greater or equal to twice the upper limit of
normal range found on two consecutive determinations.
Treatment
Patients received the following chemotherapy every 21 days:
CDDP, 100 mgm–2 intravenously on day 1 in a 2-h infusion given
with pre- and post-hydration, and VP16, 100 mg m–2 day–1 intra-
venously from day 1 to day 3 in a 2-h infusion. On day 1, the VP16
was started after the CDDP infusion. In case of severe neutropenia
(< 1500 mm–3) or thrombocytopenia (< 100 000 mm–3) treatment
was delayed for 1 week and doses reduced by 25%. The CDDP
was not administered when creatinine clearance was > 50 ml
min–1. Therapy was continued until tumour progression or as long
as the therapy was well-tolerated. Appropriate anti-emetics (anti-
HT3) were administered with each course of therapy. Concurrent
sandostatin was allowed during chemotherapy, if necessary.
Response assessment
Tumoral objective response (OR) was evaluated every three
courses during the treatment period and every 1–3 months there-
after with physical examination of patient and appropriate imaging
(ultrasound and/or CT scan) and laboratory studies. According to
WHO criteria, a complete OR was defined as a total disappearance
of all detectable tumours. A partial OR was defined as a greater
than 50% reduction in the product of the longest perpendicular
diameters of measurable lesions for at least 4 weeks in the absence
of new lesions or the progression of existing lesions. Stable
disease was defined as a reduction of tumour size of less than 50%,
or an increase in tumour size of less than 25%. Progression was
defined as a greater than 25% increase in measurable disease or the
development of new metastases. To declare a hormonal response,
it was required that this parameter be reduced to less than 50% of
the pretreatment value or to normal range. Time to progression
was the time from day 1 of the treatment to the time when a
progression was detected. Duration of objective responses was
measured from day 1 of the treatment to the time of progression
or censoring. Patient survival was the time from day 1 of the
treatment to time of death or censoring.
To evaluate prognostic factors that influenced response to treat-
ment or survival, the following parameters were analysed in
poorly differentiated NET: age, gender, primary tumour site,
hormonal secretions (defined as present or absent), prior therapies
and disease extension defined as limited or extensive stage. An
extensive stage was defined as a disease that had spread beyond
loco regional boundaries.
Toxicity was assessed after each course of chemotherapy by
physical examination, direct questioning, measurement of haema-
tological and biochemical parameters and graded according to the
WHO criteria (Miller et al, 1981).
Statistical analysis
Statistical analyses were performed using the BMDP statistical
software. Comparison of qualitative variables were made by the
Fisher’s exact test and comparison of quantitative variables by
t-tests. The survival function for time to progression and time to
death was estimated using the Kaplan–Meier method (Kaplan and
Meier, 1958) and the log-rank statistic was used to compare
survival distributions (Mantel and Haenszel, 1959). Differences
were considered significant at a P-value of less than 0.05.
RESULTS
The main characteristics of the patients are summarized in Table 1.
Twelve patients (four males, eight females) had a well-
differentiated NET and 41 (32 males, nine females) a poorly
differentiated NET.
Eight patients (one well-differentiated, seven poorly differenti-
ated) had tumours with unknown primary site. When the primary
tumour site was known, it was largely dependent upon
differentiation: 94% of the poorly differentiated tumours
compared to 54.5% of the well-differentiated tumours originated
from the foregut. Only nine tumours, one (8.3%) well-
differentiated and eight (19.5%) poorly differentiated (pancreas:
three; respiratory tract: two; mediastinum: two; head and neck:
one), had a limited stage, whereas the other 44 were metastatic.
Abnormal hormonal secretion was found in 64% of well-
differentiated and in 47% of poorly differentiated tumours.
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chemotherapy in 41.7% (5/12) of well-differentiated tumours and
in 70.7% (29/41) of poorly differentiated tumours. Among patients
with a well-differentiated tumour who received the VP16–CDDP
as first line chemotherapy, one was treated before 1991; the others
had an aggressive tumour initially classified as poorly differenti-
ated but finally classified, after pathological reviewing, as well-
differentiated. The median number of chemotherapy cycles was
four in patients with a well-differentiated tumour (range 1–8) and
six in patients with a poorly differentiated tumour (range 1–9).
Two patients with poorly differentiated tumours received sando-
statin (100 mg ´ 2 day–1) concurrently with chemotherapy.
Therapeutic results
One patient with a well-differentiated tumour died of a pulmonary
embolism after the first course of treatment and could not be eval-
uated. None of the 11 evaluable patients with a well-differentiated
tumour had a complete response; one (9.1%) showed a partial
response, four (36.4%) stable disease and six (54.5%) a progres-
sive disease. Among patients with a poorly differentiated tumour,
four (9.8%) had a complete response, 13 (31.7%) a partial
response, 14 (34.1%) stable disease and ten (24.4%) progressive
disease. The overall OR rate was 41.5% (17/41) among patients
with a poorly differentiated tumour and 9.1% (1/11) among
patients with a well-differentiated tumour. This difference was not
significant (P = 0.09) (Table 2).
Response to treatment occurred quickly. All the responders
showed an OR at the first therapeutic evaluation. The median dura-
tion of tumoural response was 8.5 months for the patient with a
well-differentiated tumour and 9.2 months (range 4.5–23.5) for
patients with poorly differentiated tumours. The duration of
tumoural response was respectively 10.6, 10.7, 12.3 and 13.3
months for the patients with complete response.
No relationship was found between response and patient age or
gender, primary tumour site, stage, hormonal secretions, prior
treatment or chemotherapy line (Table 3). It should be mentioned
that the response rate among poorly differentiated tumours of
unknown primary site was lower compared to tumours with a
known primary site (1/7 14.3% vs 16/34 47.1%, P = 0.2). Among
patients with poorly differentiated tumours who had abnormal
hormonal secretion, 87.5% of tumoural responses were accom-
panied by a hormonal response. It is noteworthy that 25% of the
hormonal responders showed no tumoural response.
Survival
After a median follow-up of 64 months (range 20–111) for patients
with a well-differentiated tumour and 36 months (range 6–68) for
patients with a poorly differentiated tumour (P = 0.001), eight
(66%) patients with a well-differentiated tumour and 26 (63%)
with a poorly differentiated tumour had died, two (16.6%) and four
(9.7%) were alive with progressive disease, one (8.3%) and five
(12.2%) were alive with stable disease, one (8.3%) and two (4.8%)
were alive in complete remission. Four patients with poorly differ-
entiated pancreatic tumours were lost to follow-up at 5, 34, 41 and
52 weeks after the beginning of treatment. None of them was a
responder and all had progressive disease when they were seen for
the last time.
Median survival for well-differentiated tumours was 17.6
months (range 8.6–72, mean = 32.5 months) and 15 months
(range 11.7–25) for poorly differentiated tumours. Median
progression-free survival was 2.3 months (range 0.9–12.1) for
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Table 1 Patient characteristics
Well-differentiated Poorly differentiated P-
tumours tumours value
Total number of patients 12 41
Male/female 4/8 32/9 0.01
Median age in years
(range) 46.5 (26–62) 53.4 (20–76)
Stage
Limited stage 1 8 NS
Extensive stage 11 33
Primary tumour site
Foregut 6 32 0.009
Pancreas 4 13
Stomach 0 3
Gallbladder 0 2
Respiratory tract 2 5
Mediastinum 0 5
Head and neck 0 4
Midgut 4 2
Small bowel 3 0
Appendix 1 0
Right colon 0 2
Hindgut 1 0
Uterus 1 0
Unknown Primary site 1 7
Abnormal hormonal
secretiona 7 (64%) 16 (47%) NS
Prior treatment 9 (75%) 24 (58%) NS
Surgery 8 13
Chemotherapy 7 13
Sandostatin 2 3
Median time between
diagnosis and start 8.0 (1.4–28.7) 3.0 (0–43.9)
of the treatment
(range)b
Median number of
courses (range) 4 (1–8) 6 (1–9)
aData available for 45 patients, bin months.
Table 2 Treatment results and survival
Well-differentiated Poorly differentiated P-value
tumours tumours
n (%) n (%)
Tumoural response
Complete regression 0 4 (9.8%) 0.09
Partial regression 1 (9.1%) 13 (31.7%)
Stable 4 (36.4%) 14 (34.1%)
Progression 6 (54.5%) 10 (24.4%)
Median duration of
response (range)9 8.5 9.24 (4.5–23.5) 0.36
Survival
Median survival
(range)a,b 17.6 (8.6–72+) 15 (11.7–25) 0.18
Median time to
progression 2.3 (0.9–12.1) 8.9 (6.7–13.4) 0.3
(range)a,b
aIn months, bKaplan–Meier method.well-differentiated and 8.9 months (range 6.7–13.4) for poorly
differentiated tumours (Table 2).
Among poorly differentiated tumours, there was a trend for a
better overall survival and better progression-free survival among
responders, but statistical significance was not reached (Table 3).
No variable was significantly associated with survival.
Toxicity
A total of 256 courses of treatment was completed. Fifty patients
were evaluated for drug toxicity (one patient died of a pulmonary
embolism after the first course of treatment and two patients
received some cycles in other centres and data about drug toxicity
were incomplete). Severe toxicity required cessation of treatment
in only one patient (1.9%). Grade 3 or 4 nausea and vomiting
occurred in 40% of the cases. Sixty per cent (30/50) of the patients
had severe neutropenia and 16% febrile aplasia. One patient died
of septic shock during aplasia. Severe anaemia and thrombo-
cytopenia occurred in 12% of the cases. With the exception of
alopecia, there were no other severe toxicities. Neurological toxi-
city grade 1 was frequent after four courses of treatment. Hearing
and renal toxicities grade 1 were rare (Table 4).
DISCUSSION
The combination of VP16 and CDDP is an ineffective treatment
for well-differentiated NET: no complete response and only 9.1%
of partial responses were observed. These results are in agreement
with Moertel et al who reported 7% of partial responses among 27
patients (Moertel et al, 1991). In this group, the median time from
diagnosis to start of treatment was only 8 months, the median
overall survival 17.6 months and the mean overall survival 32
months. This survival is very low for well-differentiated tumours.
This could probably be explained by the fact that well-differenti-
ated NET of this study which received the VP16–CDDP combina-
tion were selected because of their aggressiveness. Thus, the
prognosis of this selected group is poorer and not representative of
the prognosis of well-differentiated NET in general.
The high chemosensibility of poorly differentiated NET is
confirmed: the OR rate was 41.5% with 9.8% of complete
responses. These results seem to be less favourable than those
reported previously in smaller series: Moertel et al observed 67%
of OR with 17% of complete responses among 18 patients
(Moertel et al, 1991) and Seitz et al observed 75% of OR with 25%
of major responses among eight patients (Seitz et al, 1995). The
size of the present study population was larger than that of the
other series, therefore our estimates of tumoural response and
survival are probably more precise. The calculated 95% confi-
dence interval of the OR rate was between 45% and 89% for
Moertel et al, and from 26% to 57% in the present study.
Moertel et al used a 24-h intravenous infusion regimen in order
to enhance the therapeutic interaction of VP16 and CDDP
(Moertel et al, 1991). One could argue that a rapid injection
regimen would be less effective, but results comparable to our
infusion regimen were reported with rapid injection regimen
(Hainsworth et al, 1988).
Response to treatment occurred early and it is probably unnec-
essary to continue chemotherapy for patients who have not
responded after three courses. Nevertheless, considering the
aggressiveness of this type of tumour and the absence of alterna-
tive efficient therapy, a stabilization for patients with progressive
disease could be considered as a positive result. In this situation,
continuing the chemotherapy, if it is well tolerated, may be
beneficial.
We observed a particularly low response rate (14.3%) for
poorly-differentiated neuroendocrine carcinomas of unknown
primary site. In contrast, Hainsworth et al (1988) have reported
72% of major responses among 23 patients treated by
VP16–CDDP combination or other CDDP-based regimens.
Response to treatment increased the overall survival and the
progression-free survival by 3 months. With chemotherapy,
median overall survival was of 15–19 months compared to
6–7 months without treatment in the literature (Johnson et al,
1983; Staren et al, 1988; Rindi et al, 1996).
Haematological and neurological toxicity were a major problem
with this chemotherapy regimen. Seitz et al failed to avoid the
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Table 3 Characteristics of patients with poorly differentiated tumours
according to tumoral response
Variables Responders Non-responders P-value
Sex
Male 15 (88.2%) 17 (70.8%) 0.26a
Female 2 (11.8%) 7 (29.2%)
Age (years)
≤60 13 (76.5%) 13 (54.2%) 0.19a
>60 4 (23.5%) 11 (45.8%)
Primary tumour site
Foregut 15 (46.9%) 17 (53.1%) 0.2a
Midgut 1 (50%) 1 (50%)
Unknown 1 (14.3%) 6 (85.7%)
Stage
Limited 3 (17.6%) 5 (20.8%) 1.00a
Extended 14 (82.4%) 19 (79.2%)
Abnormal hormonal
secretion
Yes 7 (46.7%) 11 (57.9%) 0.73a
No 8 (53.3%) 8 (42.1%)
Prior chemotherapy
No 12 (70.6%) 17 (70.8%) 1.00a
Yes 5 (29.4%) 7 (29.2%)
Median survival (range)b 16.2 (9.6–) 13.1 (8.4–25.0) 0.3c
Median progression-free
survival (range)b 10.6 (8.3–16.2) 7.4 (2.5–16.3) 0.4c
aFisher’s exact test, bin months, clog-rank test.
Table 4 Treatment toxicities
Toxicity Total (%) Grade 1–2 Grade 3–4
n = 50
Non-haematological toxicity
Nausea–vomiting 38 (76%) 18 20
Neuropathy 36 (72%) 36 0
Hearing loss 7 (14%) 7 0
Renal toxicity 3 (6%) 3 0
Haematological toxicity
Leukopenia 36 (72%) 15 21
Neutropenia 35 (70%) 5 30a
Thrombocytopenia 12 (24%) 6 6
Anaemia 16 (32.7%) 10 6
aIncluding eight cases of febrile aplasia and one toxic death.complications by the systematic use of granulocyte colony-stimu-
lating factor (Seitz et al, 1995). The regimen we used was less
intensive and better tolerated with less acute toxic effects. The
treatment was stopped in only one patient because of severe toxi-
city and we observed one toxic death. Cumulative toxicity was
more frequent, but less severe compared to Moertel’s results. This
was probably related to the higher median number of courses.
We conclude that GEP NET differentiation is a main prognosis
factor which should be clearly specified when determining a thera-
peutic strategy. Poorly differentiated NET are characterized by
rapid tumour growth and chemosensitivity. Chemotherapy with
VP16 plus CDDP probably improves survival of patients with
such tumours but the prognosis remains poor: most of the patients
relapsed quickly and the 2-year survival is lower than 20%. Other
therapeutic approaches should be developed.
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